TY - JOUR
T1 - Diagnosis and outcomes of pregnant women with Zika virus infection in two municipalities of Risaralda, Colombia
T2 - Second report of the ZIKERNCOL study
AU - Rodriguez-Morales, Alfonso J.
AU - Cardona-Ospina, Jaime A.
AU - Ramirez-Jaramillo, Valeria
AU - Gaviria, Javier A.
AU - González-Moreno, Gloria María
AU - Castrillón-Spitia, Juan D.
AU - López-Villegas, Alejandra
AU - Morales-Jiménez, Estefania
AU - Ramírez-Zapata, Valentina
AU - Rueda-Merchán, German Eduardo
AU - Trujillo, Adriana M.
AU - Tabares-Villa, Fredy A.
AU - Henao-SanMartin, Valentina
AU - Murillo-Garcia, David R.
AU - Herrera-Soto, Johana Andrea
AU - Buitrago-Cañas, Marta Liliana
AU - Collins, Matthew H.
AU - Sepúlveda-Arias, Juan Carlos
AU - Londoño, José J.
AU - Bedoya-Rendón, Héctor D.
AU - de Jesús Cárdenas-Pérez, Javier
AU - Olaya, Sandra X.
AU - Lagos-Grisales, Guillermo J.
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Background: Zika virus (ZIKV) infection has emerged as a significant threat for pregnant women and newborns in populations living in or visiting Latin America. We previously reported a preliminary analysis in Sucre, Colombia, as the first group of pregnant women with RT-PCR-confirmed ZIKV (ZIKa en Embarazadas y Recién Nacidos en COLombia, ZIKERNCOL). Methods: In this second report, findings of the first 86 pregnant women from La Virginia and Dosquebradas (municipalities), Risaralda, Colombia, with RT-PCR-confirmed ZIKV infection are reported. Clinical, demographical and obstetrical findings are described. Results: All women reported ZIKV symptoms during pregnancy: 79.1% rash, 55.8% fever, among others. In addition to ZIKV, RT-PCR was positive for dengue in 18.6%; 45.3% Dengue IgM+; 5.8% RT-PCR positive for chikungunya; 3.6% Chikungunya IgM+. STORCH screening in mother: 11.6% IgG + anti-Toxoplasma gondii, 6% IgG + anti-rubella, 4.7% IgG + CMV. The rest of STORCH tests were negative. Microcephaly was observed in 2.4% of the newborns. No calcifications or other CNS alterations were detected. One newborn had cleft palate and one had bilateral renal ectopy. Conclusions: The rate of microcephaly in our cohort was consistent with other studies. Pregnant women in endemic areas should be followed and tested according to standard protocols, and asymptomatic ZIKV infection should be considered. Long-term follow-up of children is required in the congenital Zika syndrome (CZS) assessment.
AB - Background: Zika virus (ZIKV) infection has emerged as a significant threat for pregnant women and newborns in populations living in or visiting Latin America. We previously reported a preliminary analysis in Sucre, Colombia, as the first group of pregnant women with RT-PCR-confirmed ZIKV (ZIKa en Embarazadas y Recién Nacidos en COLombia, ZIKERNCOL). Methods: In this second report, findings of the first 86 pregnant women from La Virginia and Dosquebradas (municipalities), Risaralda, Colombia, with RT-PCR-confirmed ZIKV infection are reported. Clinical, demographical and obstetrical findings are described. Results: All women reported ZIKV symptoms during pregnancy: 79.1% rash, 55.8% fever, among others. In addition to ZIKV, RT-PCR was positive for dengue in 18.6%; 45.3% Dengue IgM+; 5.8% RT-PCR positive for chikungunya; 3.6% Chikungunya IgM+. STORCH screening in mother: 11.6% IgG + anti-Toxoplasma gondii, 6% IgG + anti-rubella, 4.7% IgG + CMV. The rest of STORCH tests were negative. Microcephaly was observed in 2.4% of the newborns. No calcifications or other CNS alterations were detected. One newborn had cleft palate and one had bilateral renal ectopy. Conclusions: The rate of microcephaly in our cohort was consistent with other studies. Pregnant women in endemic areas should be followed and tested according to standard protocols, and asymptomatic ZIKV infection should be considered. Long-term follow-up of children is required in the congenital Zika syndrome (CZS) assessment.
KW - Colombia
KW - Complications
KW - Congenital Zika syndrome
KW - Microcephaly
KW - Pregnant
KW - Zika virus
UR - http://www.scopus.com/inward/record.url?scp=85048568405&partnerID=8YFLogxK
U2 - 10.1016/j.tmaid.2018.06.006
DO - 10.1016/j.tmaid.2018.06.006
M3 - Artículo
C2 - 29894797
AN - SCOPUS:85048568405
SN - 1477-8939
VL - 25
SP - 20
EP - 25
JO - Travel Medicine and Infectious Disease
JF - Travel Medicine and Infectious Disease
ER -